264622-53-9 Usage
Uses
Used in Pharmaceutical Industry:
MRS 1706 is used as a selective and potent inverse agonist for the adenosine A2B receptor, which plays a crucial role in various physiological and pathological processes. Its high binding affinity makes it a promising candidate for the development of new therapeutic strategies targeting adenosine receptor-mediated diseases.
Used in Research Applications:
MRS 1706 is used as a research tool to study the role of adenosine A2B receptors in cellular and molecular processes. Its selective binding to the A2B receptor allows researchers to investigate the specific functions and interactions of this receptor in various experimental settings, contributing to a better understanding of adenosine receptor biology and its potential therapeutic applications.
Used in Drug Development:
MRS 1706 is used as a lead compound in the development of new drugs targeting adenosine A2B receptors. Its high selectivity and potency make it an attractive starting point for the design and optimization of novel therapeutic agents with improved pharmacological properties, such as increased selectivity, better bioavailability, and reduced side effects.
Biological Activity
Potent and selective adenosine A 2B receptor inverse agonist (K i values are 1.39, 157, 112 and 230 nM for human A 2B , A 1 , A 2A and A 3 receptors respectively).
Check Digit Verification of cas no
The CAS Registry Mumber 264622-53-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,4,6,2 and 2 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 264622-53:
(8*2)+(7*6)+(6*4)+(5*6)+(4*2)+(3*2)+(2*5)+(1*3)=139
139 % 10 = 9
So 264622-53-9 is a valid CAS Registry Number.
264622-53-9Relevant articles and documents
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors
Kim, Yong-Chul,Ji, Xiao-Duo,Melman, Neli,Linden, Joel,Jacobson, Kenneth A.
, p. 1165 - 1172 (2007/10/03)
No highly selective antagonists of the A(2B) adenosine receptor (AR) have been reported; however such antagonists have therapeutic potential as antiasthmatic agents. Here we report the synthesis of potent and selective A(2B) receptor antagonists. The stru